Details of the Drug

General Information of Drug (ID: DMFXEWT)

Drug Name
Chloramphenicol
Synonyms
Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin® D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Boutonneuse fever N.A. Approved [2]
Meningococcal meningitis N.A. Approved [2]
Rickettsiosis N.A. Approved [2]
Paratyphoid fever N.A. Investigative [2]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 323.13
Logarithm of the Partition Coefficient (xlogp) 1.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
82% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.4 mL/min/kg [5]
Elimination
5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 - 3.5 hours (in adults with normal hepatic and renal function), and 3 - 4 hours (in patients with impaired renal function half-life) [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 309.46848 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.34% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.94 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 2.5 mg/mL [3]
Chemical Identifiers
Formula
C11H12Cl2N2O5
IUPAC Name
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
Canonical SMILES
C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
InChI
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
InChIKey
WIIZWVCIJKGZOK-RKDXNWHRSA-N
Cross-matching ID
PubChem CID
5959
ChEBI ID
CHEBI:17698
CAS Number
56-75-7
DrugBank ID
DB00446
TTD ID
D0X6IU
VARIDT ID
DR00989
INTEDE ID
DR0298
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA) TTLFGBV NOUNIPROTAC Binder [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Chloramphenicolase (chlR) DE26V9J A0A5M4B0P0_9BACT Substrate [10]
Glycerol-3-phosphate dehydrogenase (gpsA) DEFVHQU A0A411LCN0_ERYRH Substrate [11], [12]
Chloramphenicolase (chlR) DEMUBWL A0A5M4B0P0_9BACT Substrate [10]
Chloramphenicolase (chlR) DECMT89 A0A5M4B0P0_9BACT Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Gene/Protein Processing [13]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [14]
Catalase (CAT) OTHEBX9R CATA_HUMAN Gene/Protein Processing [15]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Gene/Protein Processing [13]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Gene/Protein Processing [16]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Protein Interaction/Cellular Processes [17]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Gene/Protein Processing [17]
Cytochrome c oxidase subunit 1 (COX1) OTG3O9BN COX1_HUMAN Gene/Protein Processing [17]
Cytochrome c oxidase subunit 2 (COX2) OTTMVBJJ COX2_HUMAN Gene/Protein Processing [18]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chloramphenicol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Decreased metabolism of Chloramphenicol caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [20]
Glibenclamide DM8JXPZ Moderate Increased plasma concentration of Chloramphenicol and Glibenclamide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [21]
Tolazamide DMIHRNA Moderate Increased plasma concentration of Chloramphenicol and Tolazamide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [21]
Glipizide DMZA5PQ Moderate Increased plasma concentration of Chloramphenicol and Glipizide due to competitive binding of plasma proteins. Acute diabete complication [5A2Y] [21]
Midostaurin DMI6E0R Moderate Decreased metabolism of Chloramphenicol caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [23]
Oliceridine DM6MDCF Major Decreased metabolism of Chloramphenicol caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [24]
Donepezil DMIYG7Z Minor Decreased metabolism of Chloramphenicol caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [25]
Ivabradine DM0L594 Moderate Decreased metabolism of Chloramphenicol caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [23]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Chloramphenicol caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [26]
Methylphenobarbital DMDSWAG Moderate Decreased metabolism of Chloramphenicol caused by Methylphenobarbital mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [27]
Cilostazol DMZMSCT Moderate Decreased metabolism of Chloramphenicol caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [28]
Budesonide DMJIBAW Moderate Decreased metabolism of Chloramphenicol caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [29]
Cariprazine DMJYDVK Moderate Decreased metabolism of Chloramphenicol caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [30]
Pexidartinib DMS2J0Z Major Decreased metabolism of Chloramphenicol caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [31]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Chloramphenicol caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
HKI-272 DM6QOVN Major Decreased metabolism of Chloramphenicol caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
LY2835219 DM93VBZ Moderate Decreased metabolism of Chloramphenicol caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Palbociclib DMD7L94 Moderate Decreased metabolism of Chloramphenicol caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Bosutinib DMTI8YE Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [23]
Macitentan DMP79A1 Moderate Decreased metabolism of Chloramphenicol caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [35]
PF-04449913 DMSB068 Moderate Decreased metabolism of Chloramphenicol caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [36]
Anisindione DM2C48U Moderate Decreased metabolism of Chloramphenicol caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [37]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Chloramphenicol caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [38]
Levobupivacaine DM783CH Moderate Decreased metabolism of Chloramphenicol caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [23]
Methohexital DM7YMIT Moderate Increased metabolism of Chloramphenicol caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [37]
Alfentanil DMVO0UB Moderate Decreased metabolism of Chloramphenicol caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [39]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Chloramphenicol due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [40]
Mifepristone DMGZQEF Moderate Decreased metabolism of Chloramphenicol caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [41]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Chloramphenicol caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [23]
Ivacaftor DMZC1HS Major Decreased metabolism of Chloramphenicol caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [23]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [42]
Aprepitant DM053KT Moderate Decreased metabolism of Chloramphenicol caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [43]
Escitalopram DMFK9HG Minor Decreased metabolism of Chloramphenicol caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [44]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Chloramphenicol caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Primidone DM0WX6I Moderate Increased metabolism of Chloramphenicol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Stiripentol DMMSDOY Moderate Decreased metabolism of Chloramphenicol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Ethotoin DMXWOCP Moderate Decreased metabolism of Chloramphenicol caused by Ethotoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Phenobarbital DMXZOCG Moderate Increased metabolism of Chloramphenicol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Cannabidiol DM0659E Minor Decreased metabolism of Chloramphenicol caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [23]
Bay 80-6946 DMLOS5R Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [47]
Tazemetostat DMWP1BH Major Decreased metabolism of Chloramphenicol caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [48]
Solifenacin DMG592Q Moderate Decreased metabolism of Chloramphenicol caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [49]
Mirabegron DMS1GYT Minor Decreased metabolism of Chloramphenicol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [50]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Chloramphenicol caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [51]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Chloramphenicol caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [52]
Cisapride DMY7PED Major Decreased metabolism of Chloramphenicol caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [53]
Ripretinib DM958QB Moderate Decreased metabolism of Chloramphenicol caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [54]
Avapritinib DMK2GZX Major Decreased metabolism of Chloramphenicol caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [23]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Chloramphenicol caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [55]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Chloramphenicol caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [54]
Rifampin DMA8J1G Moderate Increased metabolism of Chloramphenicol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [56]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Chloramphenicol and Brentuximab vedotin. Hodgkin lymphoma [2B30] [57]
MK-1439 DM215WE Minor Decreased metabolism of Chloramphenicol caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Dolutegravir DMCZGRE Minor Decreased metabolism of Chloramphenicol caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Chloramphenicol and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [60]
Lopinavir DMITQS0 Minor Decreased metabolism of Chloramphenicol caused by Lopinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [23]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Chloramphenicol caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Maraviroc DMTL94F Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [61]
BMS-201038 DMQTAGO Major Decreased metabolism of Chloramphenicol caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [54]
Aliskiren DM1BV7W Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [38]
Levamlodipine DM92S6N Moderate Decreased metabolism of Chloramphenicol caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [38]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Chloramphenicol caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [23]
Retapamulin DM9JXB7 Minor Decreased metabolism of Chloramphenicol caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [62]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Chloramphenicol caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [54]
Amobarbital DM0GQ8N Moderate Increased metabolism of Chloramphenicol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Chloramphenicol caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [63]
Naloxegol DML0B41 Major Decreased metabolism of Chloramphenicol caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [23]
Pemigatinib DM819JF Major Decreased metabolism of Chloramphenicol caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [23]
Brigatinib DM7W94S Major Decreased metabolism of Chloramphenicol caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [54]
Ceritinib DMB920Z Moderate Decreased metabolism of Chloramphenicol caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [64]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Chloramphenicol caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [65]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Chloramphenicol caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [66]
Osimertinib DMRJLAT Moderate Decreased metabolism of Chloramphenicol caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Chloramphenicol caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [68]
Capmatinib DMYCXKL Moderate Decreased metabolism of Chloramphenicol caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [69]
Selpercatinib DMZR15V Major Decreased metabolism of Chloramphenicol caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [23]
Chloroquine DMSI5CB Moderate Decreased metabolism of Chloramphenicol caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [54]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Chloramphenicol caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [54]
Idelalisib DM602WT Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Idelalisib. Mature B-cell leukaemia [2A82] [70]
IPI-145 DMWA24P Moderate Decreased metabolism of Chloramphenicol caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [71]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Chloramphenicol caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [72]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Chloramphenicol caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [73]
Selumetinib DMC7W6R Major Decreased metabolism of Chloramphenicol caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [74]
LGX818 DMNQXV8 Major Decreased metabolism of Chloramphenicol caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [75]
Ubrogepant DM749I3 Moderate Decreased metabolism of Chloramphenicol caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [76]
Rimegepant DMHOAUG Moderate Decreased metabolism of Chloramphenicol caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [77]
Flibanserin DM70DTN Major Decreased metabolism of Chloramphenicol caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [78]
Panobinostat DM58WKG Moderate Decreased metabolism of Chloramphenicol caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [79]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Chloramphenicol and Thalidomide. Multiple myeloma [2A83] [60]
Siponimod DM2R86O Major Decreased metabolism of Chloramphenicol caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [54]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Chloramphenicol and Ocrelizumab. Multiple sclerosis [8A40] [80]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Chloramphenicol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [23]
Nilotinib DM7HXWT Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [81]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Chloramphenicol caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [23]
Dasatinib DMJV2EK Moderate Decreased metabolism of Chloramphenicol caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [82]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Chloramphenicol and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [83]
Modafinil DMYILBE Minor Decreased metabolism of Chloramphenicol caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [54]
Entrectinib DMMPTLH Major Decreased metabolism of Chloramphenicol caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [54]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Chloramphenicol caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [84]
S-297995 DM26IH8 Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [23]
Olaparib DM8QB1D Moderate Decreased metabolism of Chloramphenicol caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [85]
Butorphanol DM5KYPJ Major Decreased metabolism of Chloramphenicol caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [86]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Chloramphenicol caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [87]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Chloramphenicol caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [88]
Oxycodone DMXLKHV Major Decreased metabolism of Chloramphenicol caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [54]
Istradefylline DM20VSK Moderate Decreased metabolism of Chloramphenicol caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [89]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Chloramphenicol caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [90]
Lefamulin DME6G97 Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [91]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Chloramphenicol caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [92]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Chloramphenicol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [93]
Enzalutamide DMGL19D Moderate Decreased metabolism of Chloramphenicol caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [94]
Darolutamide DMV7YFT Minor Decreased clearance of Chloramphenicol due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [95]
Silodosin DMJSBT6 Moderate Decreased metabolism of Chloramphenicol caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [96]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Chloramphenicol caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [97]
Everolimus DM8X2EH Major Decreased metabolism of Chloramphenicol caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [98]
Axitinib DMGVH6N Moderate Decreased metabolism of Chloramphenicol caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [23]
Temsirolimus DMS104F Moderate Decreased metabolism of Chloramphenicol caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [99]
Upadacitinib DM32B5U Moderate Decreased metabolism of Chloramphenicol caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [100]
Quetiapine DM1N62C Moderate Decreased metabolism of Chloramphenicol caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [101]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Chloramphenicol caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [102]
Pimozide DMW83TP Major Decreased metabolism of Chloramphenicol caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [54]
Fentanyl DM8WAHT Moderate Decreased metabolism of Chloramphenicol caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [103]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Chloramphenicol caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [104]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Chloramphenicol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [105]
LDE225 DMM9F25 Moderate Decreased metabolism of Chloramphenicol caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [106]
Larotrectinib DM26CQR Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [54]
Cyclophosphamide DM4O2Z7 Minor Decreased metabolism of Chloramphenicol caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Docetaxel DMDI269 Moderate Decreased metabolism of Chloramphenicol caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [107]
Armodafinil DMGB035 Minor Decreased metabolism of Chloramphenicol caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
LEE011 DMMX75K Moderate Decreased metabolism of Chloramphenicol caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Ivermectin DMDBX5F Moderate Decreased metabolism of Chloramphenicol caused by Ivermectin mediated inhibition of CYP450 enzyme. Strongyloidiasis [1F6B] [23]
Warfarin DMJYCVW Moderate Decreased metabolism of Chloramphenicol caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [37]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Chloramphenicol caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [108]
Apixaban DM89JLN Moderate Decreased clearance of Chloramphenicol due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [23]
Clopidogrel DMOL54H Moderate Decreased metabolism of Chloramphenicol caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [109]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Chloramphenicol caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [110]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Chloramphenicol and Azathioprine. Transplant rejection [NE84] [54]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Chloramphenicol due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [40]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Chloramphenicol caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [111]
Tolbutamide DM02AWV Moderate Increased plasma concentration of Chloramphenicol and Tolbutamide due to competitive binding of plasma proteins. Type 2 diabetes mellitus [5A11] [21]
Saxagliptin DMGXENV Moderate Decreased metabolism of Chloramphenicol caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [23]
Chlorpropamide DMPHZQE Moderate Increased plasma concentration of Chloramphenicol and Chlorpropamide due to competitive binding of plasma proteins. Type 2 diabetes mellitus [5A11] [21]
Elagolix DMB2C0E Moderate Decreased metabolism of Chloramphenicol caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [112]
Fluticasone DMGCSVF Moderate Decreased metabolism of Chloramphenicol caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [54]
Propafenone DMPIBJK Moderate Decreased metabolism of Chloramphenicol caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [113]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Chloramphenicol and Ganciclovir. Virus infection [1A24-1D9Z] [54]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Chloramphenicol and Valganciclovir. Virus infection [1A24-1D9Z] [54]
⏷ Show the Full List of 148 DDI Information of This Drug

References

1 Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
2 Chloramphenicol FDA Label
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
8 Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
9 Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
10 The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
11 Porcine beta-defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. Mol Immunol. 2008 Jan;45(2):386-94.
12 Dehydrogenase activity of chlornitromycin-resistant variants of Erysipelothrix rhusiopathiae. Izv Mikrobiol Inst (Sofiia). 1969;20:257-62.
13 Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
14 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
15 Chloramphenicol-induced oxidative stress in human neutrophils. Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):349-53.
16 Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion. Toxicol Sci. 2010 Jul;116(1):140-50. doi: 10.1093/toxsci/kfq085. Epub 2010 Mar 25.
17 Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
18 A genome-wide analysis of targets of macrolide antibiotics in mammalian cells. J Biol Chem. 2020 Feb 14;295(7):2057-2067. doi: 10.1074/jbc.RA119.010770. Epub 2020 Jan 8.
19 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
20 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
21 Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K "Interaction of tolbutamide and chloramphenicol in diabetic patients." Int J Clin Pharmacol 15 (1977): 7-12. [PMID: 838527]
22 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
23 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
25 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
26 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
27 Bloxham RA, Durbin GM, Johnson T, Winterborn MH "Chloramphenicol and phenobarbitone--a drug interaction." Arch Dis Child 54 (1979): 76-7. [PMID: 311186]
28 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
29 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
30 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
31 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
32 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
33 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
34 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
35 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
36 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
37 Ambrose PJ "Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate." Clin Pharmacokinet 9 (1984): 222-38. [PMID: 6375931]
38 Canadian Pharmacists Association.
39 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
40 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
41 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
42 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
43 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
44 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
45 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
46 Christensen LK, Skovsted L "Inhibition of drug metabolism by chloramphenicol." Lancet 2 (1969): 1397-9. [PMID: 4188280]
47 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
48 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
49 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
50 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
51 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
52 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
53 Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
54 Cerner Multum, Inc. "Australian Product Information.".
55 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
56 Prober CG "Effect of rifampin on chloramphenicol levels." N Engl J Med 312 (1985): 788-9. [PMID: 3974656]
57 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
58 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
59 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
60 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
61 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
63 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
64 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
66 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
67 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
68 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
69 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
70 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
71 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
72 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
73 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
74 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
76 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
77 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
78 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
79 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
80 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
81 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
83 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
84 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
85 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
86 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
87 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
88 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
89 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
90 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
91 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
92 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
93 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
94 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
95 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
96 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
97 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
98 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
100 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
101 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
102 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
103 Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997): 1072-80. [PMID: 9311623]
104 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
105 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
106 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
107 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
108 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
109 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
110 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
111 Schulman SL, Shaw LM, Jabs K, Leonard MB, Brayman KL "Interaction between tacrolimus and chloramphenicol in a renal transplant recipient." Transplantation 65 (1998): 1397-8. [PMID: 9625026]
112 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
113 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.